© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
April 10, 2020
AXS-07 showed statistical significance for migraine pain freedom at 90 minutes, and at every time point after.
December 24, 2019
The oral CGRP antagonist becomes the first in its class approved for the indication.
October 11, 2019
The oral therapy showed benefit in reducing symptoms and migraine-related pain, as well as aura, within 2 hours of administration.
August 08, 2019
Drinking more than 3 servings of caffeinated beverages per day was associated with an increase in migraine headaches.
July 11, 2019
Rimegepant (rimegepant Zydis), which is a novel therapy for treatment of acute migraines, was found to reduce bothersome suymptoms and eliminate pain in a phase 3 clinical trial.
June 05, 2019
The approval is based on the findings of a 106-adult patient trial which assessed mean weekly headache episodes.
April 03, 2019
Overconfidence, anchoring errors, biases, and other factors have all led to misdiagnoses at points in my internal medicine career.
April 02, 2019
The Complete Response Letter highlights issues in the Chemistry, Manufacturing, and Controls section of the application.
March 13, 2019
While the diseases appear to be unrelated, there may be underlying factors that link them together.
March 11, 2019
An FDA decision on the application is expected by December 27, 2019.